Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups (Q74616021)
scientific article published on 01 February 1999
Language:
(P31) (Q13442814)
(P304) 267-268
(P407) (Q1860)
(P433) 1-2
(P478) 31
(P577) Monday, February 1, 1999
(P1433) (Q7834825)
(P1476) "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" (language: en)
(P2093) H Ekberg
L Bäckman
G Tufveson
G Tydén
(P2860) (Q40891371)
(Q68455768)
(Q67912244)
(Q71983561)
(Q35759097)
(Q24600912)
(Q74038855)
(Q77916212)
(Q42670216)
(Q47887130)
other details
description scientific article published on 01 February 1999

External Links